ATE345115T1 - Zusammensetzungen zur behandlung von chlamydiale assozierten krankheiten - Google Patents

Zusammensetzungen zur behandlung von chlamydiale assozierten krankheiten

Info

Publication number: ATE345115T1
Authority: AT; Austria
Prior art keywords: treatment; compositions; chlamydial; associated diseases; trimoxazole
Prior art date: 1998-06-30

Application number

AT99928901T

Other languages

English (en)

Inventor

Karl William Baumgart

Highway Pacific

Thomas Julius Borody

Original Assignee

Karl William Baumgart

Borody Thomas J

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-30

Filing date

1999-06-30

Publication date

2006-12-15

1999-06-30 Application filed by Karl William Baumgart, Borody Thomas J filed Critical Karl William Baumgart

2006-12-15 Application granted granted Critical

2006-12-15 Publication of ATE345115T1 publication Critical patent/ATE345115T1/de

Links

239000000203 mixture Substances 0.000 title abstract 2
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 abstract 2
WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 abstract 2
229930189077 Rifamycin Natural products 0.000 abstract 2
239000004098 Tetracycline Substances 0.000 abstract 2
239000003242 anti bacterial agent Substances 0.000 abstract 2
229940088710 antibiotic agent Drugs 0.000 abstract 2
239000004599 antimicrobial Substances 0.000 abstract 2
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 abstract 2
229960005091 chloramphenicol Drugs 0.000 abstract 2
229940047766 co-trimoxazole Drugs 0.000 abstract 2
239000003120 macrolide antibiotic agent Substances 0.000 abstract 2
229940041033 macrolides Drugs 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
230000002265 prevention Effects 0.000 abstract 2
150000007660 quinolones Chemical class 0.000 abstract 2
BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 abstract 2
229940081192 rifamycins Drugs 0.000 abstract 2
229940124530 sulfonamide Drugs 0.000 abstract 2
150000003456 sulfonamides Chemical class 0.000 abstract 2
235000019364 tetracycline Nutrition 0.000 abstract 2
150000003522 tetracyclines Chemical class 0.000 abstract 2
229940040944 tetracyclines Drugs 0.000 abstract 2
241000606161 Chlamydia Species 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
244000005700 microbiome Species 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT99928901T 1998-06-30 1999-06-30 Zusammensetzungen zur behandlung von chlamydiale assozierten krankheiten ATE345115T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
AUPP4376A AUPP437698A0 (en)	1998-06-30	1998-06-30	Methods for treatment of coronary, carotid and other vascular disease

Publications (1)

Publication Number	Publication Date
ATE345115T1 true ATE345115T1 (de)	2006-12-15

Family

ID=3808619

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99928901T ATE345115T1 (de)	1998-06-30	1999-06-30	Zusammensetzungen zur behandlung von chlamydiale assozierten krankheiten

Country Status (10)

Country	Link
US (1)	US6475518B1 (de)
EP (2)	EP1754472B1 (de)
JP (3)	JP4651816B2 (de)
AT (1)	ATE345115T1 (de)
AU (2)	AUPP437698A0 (de)
CA (2)	CA2684402C (de)
DE (1)	DE69934010T2 (de)
ES (2)	ES2514469T3 (de)
NZ (1)	NZ509504A (de)
WO (1)	WO2000001378A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6258532B1 (en)	1997-08-14	2001-07-10	Vanderbilt University	Methods for in vitro susceptibility testing of chlamydia
US6710033B1 (en)	1996-08-14	2004-03-23	Vanderbilt University	Methods and treatment of multiple sclerosis
US6890526B2 (en)	1997-05-06	2005-05-10	Vanderbilt University	Methods and reagents for the treatment of multiple sclerosis
US6756369B2 (en) *	1997-05-06	2004-06-29	Vanderbilt University	Diagnosis and management of infection caused by Chlamydia
AU3760400A (en) *	1999-03-19	2000-10-09	Vanderbilt University	Methods and reagents for the diagnosis and treatment of multiple sclerosis
US6991807B2 (en) *	2000-02-24	2006-01-31	Advancis Pharmaceutical, Corp.	Antibiotic composition
US6623757B2 (en) *	2000-02-24	2003-09-23	Advancis Pharmaceutical Corp.	Antibiotic composition
ES2312422T3 (es) *	2000-03-22	2009-03-01	PHARMACIA & UPJOHN COMPANY LLC	Formulacion de comprimido de oxazolidinona.
US6514529B2 (en)	2000-03-22	2003-02-04	Pharmacia & Upjohn Company	Oxazolidinone tablet formulation
IT1318459B1 (it)	2000-04-11	2003-08-25	Zambon Spa	Uso del tiamfenicolo e di suoi derivati per la preparazione dicomposizioni farmaceutiche utili per il trattamento di infezioni da
US20020169112A1 (en) *	2001-05-08	2002-11-14	Luc Montagnier	Combined treatments and methods for treatment of mycoplasma and mycoplasma-like organism infections
EP1262185A1 (de) *	2001-05-30	2002-12-04	New Pharma Research Sweden AB	Synergistische Antibiotika-enthaltende Zusammensetzungen
WO2003004098A1 (en) *	2001-07-06	2003-01-16	Sucampo Ag	Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
UA79952C2 (en) *	2001-12-10	2007-08-10	Kabulesh Mafatlal Khamar	MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
AUPS017702A0 (en) *	2002-01-25	2002-02-14	Atopic Pty Ltd	Methods and compositions for the treatment of asthma and related disorders
AUPS088702A0 (en)	2002-03-04	2002-03-28	Borody, Thomas Julius	Electrolyte purgative
CA2478121A1 (en) *	2002-03-07	2003-09-18	Advancis Pharmaceutical Corporation	Antibiotic composition
EP1531828A4 (de) *	2002-05-23	2005-11-02	Activbiotics Inc	Verfahren zur behandlung von bakterieninfektionen und damit zusammenhängenden erkrankungen
US20090149453A1 (en) *	2002-05-23	2009-06-11	Activbiotics Pharma Llc	Methods and compositions for treating bacterial infections and diseases associated therewith
US20040077533A1 (en) *	2002-05-23	2004-04-22	Sayada Chalom B.	Methods and compositions for treating bacterial infections and diseases associated therewith
US7108992B2 (en) *	2002-11-27	2006-09-19	St. Jude Children's Research Hospital	ATM kinase compositions and methods
US6916627B2 (en) *	2002-11-27	2005-07-12	St. Jude Children's Research Hospital	ATM kinase compositions and methods
EP1575567A4 (de) *	2002-12-12	2008-10-08	Activbiotics Inc	Verfahren und reagentien zur behandlungoder vorbeugung von arteriosklerose und damit einhergehenden krankheiten
US20040126414A1 (en) *	2002-12-12	2004-07-01	Michaelis Arthur F.	Methods and compositions for treating and preventing ear infections
US20050013835A1 (en) *	2003-07-15	2005-01-20	Pfizer Inc.	Stable non-dihydrate azithromycin oral suspensions
RU2254123C2 (ru) *	2003-08-11	2005-06-20	Государственное научное учреждение Институт экспериментальной ветеринарии Сибири и Дальнего Востока Сибирского отделения Россельхозакадемии (ГНУ ИЭВСиДВ СО РАСХН)	Препарат для лечения гемобартонеллеза кошек и способ его применения
WO2005027961A2 (en) *	2003-09-23	2005-03-31	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Chlamydia pmpd autotransporter and its role as adhesin
CA2555304C (en)	2004-02-06	2016-06-28	Nicolas Peter Shortis	Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
US20080306029A1 (en) *	2004-05-28	2008-12-11	Salix Pharmaceuticals, Inc.	Prevention, Treatment, and Amelioration of Radiation Induced Enteritis
US20110097402A1 (en) *	2004-09-30	2011-04-28	Covalon Technologies Inc.	Non-adhesive elastic gelatin matrices
WO2006057429A1 (ja) *	2004-11-24	2006-06-01	Nanocarrier Co., Ltd.	ブロックコポリマーのモーフォロジ－の変化方法
US7452872B2 (en)	2005-08-24	2008-11-18	Salix Pharmaceuticals, Inc.	Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
WO2007025146A2 (en) *	2005-08-24	2007-03-01	Salix Pharmaceuticals, Inc.	Balsalazide formulations and manufacture and use thereof
US8921344B2 (en) *	2006-11-03	2014-12-30	Salix Pharmaceuticals, Inc.	Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
FR2891744B1 (fr) *	2005-10-06	2009-10-09	France Etat Armement	Application a la chimioprophylaxie du paludisme d'une association de chloroquine et de doxycycline
WO2009015214A2 (en) *	2007-07-24	2009-01-29	Wayne State University	Nanoparticles for imaging and treating chlamydial infection
EP2365802B1 (de)	2008-11-11	2017-08-02	The Board of Regents,The University of Texas System	Mikrokapseln von rapamycin und deren verwendung zur behandlung von krebs
DE112010004110T8 (de)	2009-10-22	2012-12-06	Thomas Julius Borody	Neue parasitentherapie
US9283211B1 (en)	2009-11-11	2016-03-15	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
EP2563117B1 (de)	2010-04-26	2018-02-21	Salix Pharmaceuticals, Ltd.	Formulierungen aus und verwendungen von 2-hydroxy-5-phenylazobenzoesäurederivaten zur behandlung männlicher patienten
CN103338768B (zh)	2010-12-13	2019-04-19	萨利克斯药品有限公司	胃和结肠的配制剂及其制备和使用方法
WO2013025105A1 (en) *	2011-08-16	2013-02-21	/Purac Biochem B.V.	Recovery of carboxylic acid from their magnesium salts by precipitation using hydrochloric acid, useful for fermentation broth work-up
HUE043852T2 (hu)	2012-07-27	2019-09-30	Redhill Biopharma Ltd	A vastagbél kiürítésére szolgáló készítmények és a készítmények elõállítási módszerei
EP2968281B1 (de)	2013-03-13	2020-08-05	The Board of Regents of The University of Texas System	Mtor-hemmer zur vorbeugung von darmpolypenwachstum
AU2014373683B2 (en)	2013-12-31	2020-05-07	Rapamycin Holdings, Llc	Oral rapamycin nanoparticle preparations and use
US9700544B2 (en)	2013-12-31	2017-07-11	Neal K Vail	Oral rapamycin nanoparticle preparations
CA2997671A1 (en) *	2015-10-06	2017-04-13	Redhill Biopharma Ltd.	Combination therapies for treating cancer
US11197872B2 (en)	2017-04-21	2021-12-14	Lunella Biotech, Inc.	Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)
CA3060509A1 (en)	2017-04-21	2018-10-25	Federica Sotgia	Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy
KR20200010343A (ko)	2017-05-19	2020-01-30	루넬라 바이오테크 인코포레이티드	안티미토신: 암 줄기 세포를 근절하기 위한 미토콘드리아 생물발생의 표적화 억제제
US12006553B2 (en)	2017-05-19	2024-06-11	Lunella Biotech, Inc.	Companion diagnostics for mitochondrial inhibitors
RU2020102908A (ru)	2017-06-26	2021-07-27	Лунелла Байотек, Инк.	Митокетосцины: митохондриальная терапия, нацеленная на кетоновый метаболизм в раковых клетках
WO2019148249A1 (en) *	2018-02-01	2019-08-08	Centre For Digestive Diseases	Compositions for treating infective arterial diseases and related conditions
RU2684728C1 (ru) *	2018-05-21	2019-04-12	федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный аграрный университет"	Препарат на основе пчелиного маточного молочка для лечения мелких домашних животных при гемобартонеллезе
CN115867288A (zh) *	2020-03-27	2023-03-28	维克多瑞有限公司	用于治疗呼吸系统病症的组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US588550A (en)		1897-08-24		Alarm-clock
GB1463550A (en)	1974-08-06	1977-02-02	Bodrero G	Pharmaceutical composition
GB2189699A (en)	1986-04-30	1987-11-04	Haessle Ab	Coated acid-labile medicaments
FI883067A7 (fi) *	1988-06-27	1989-12-28	Labsystems Oy	Foerfarande foer behandling av koronarkaerlsjukdom.
US5914132A (en)	1993-02-26	1999-06-22	The Procter & Gamble Company	Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
GB9416600D0 (en)	1994-08-17	1994-10-12	Smithkline Beecham Plc	Pharmaceutical formulation
US5624704A (en)	1995-04-24	1997-04-29	Baylor College Of Medicine	Antimicrobial impregnated catheters and other medical implants and method for impregnating catheters and other medical implants with an antimicrobial agent
US6080757A (en) *	1996-06-06	2000-06-27	Pfizer Inc	Antibiotic quinolones and derivatives
US6838552B1 (en) *	1997-08-14	2005-01-04	Vanderbilt University	Diagnosis and management of infection caused by Chlamydia
US5811121A (en)	1997-01-29	1998-09-22	Eastman Chemical Company	PH-sensitive coatings based on cellulose acetoacetate
JP2002512622A (ja) *	1997-05-06	2002-04-23	バンダービルトユニバーシティー	クラミジアにより引き起こされる感染の診断および管理のための抗クラミジア剤の組成物

1998
- 1998-06-30 AU AUPP4376A patent/AUPP437698A0/en not_active Abandoned
1999
- 1999-06-20 US US09/736,029 patent/US6475518B1/en not_active Expired - Lifetime
- 1999-06-30 EP EP06023648.6A patent/EP1754472B1/de not_active Expired - Lifetime
- 1999-06-30 CA CA2684402A patent/CA2684402C/en not_active Expired - Lifetime
- 1999-06-30 ES ES06023648.6T patent/ES2514469T3/es not_active Expired - Lifetime
- 1999-06-30 AT AT99928901T patent/ATE345115T1/de not_active IP Right Cessation
- 1999-06-30 AU AU45919/99A patent/AU757293B2/en not_active Expired
- 1999-06-30 NZ NZ509504A patent/NZ509504A/en not_active IP Right Cessation
- 1999-06-30 CA CA2336593A patent/CA2336593C/en not_active Expired - Lifetime
- 1999-06-30 EP EP99928901A patent/EP1093363B1/de not_active Expired - Lifetime
- 1999-06-30 DE DE69934010T patent/DE69934010T2/de not_active Expired - Lifetime
- 1999-06-30 ES ES99928901T patent/ES2278449T3/es not_active Expired - Lifetime
- 1999-06-30 JP JP2000557825A patent/JP4651816B2/ja not_active Expired - Lifetime
- 1999-06-30 WO PCT/AU1999/000528 patent/WO2000001378A1/en not_active Ceased
2010
- 2010-03-29 JP JP2010074109A patent/JP5335726B2/ja not_active Expired - Lifetime
2013
- 2013-04-02 JP JP2013076511A patent/JP2013147504A/ja active Pending

Also Published As

Publication number	Publication date
JP4651816B2 (ja)	2011-03-16
JP2002519374A (ja)	2002-07-02
ES2514469T3 (es)	2014-10-28
JP2013147504A (ja)	2013-08-01
CA2684402C (en)	2012-10-30
AU4591999A (en)	2000-01-24
EP1754472A3 (de)	2009-08-26
EP1093363A4 (de)	2003-09-24
HK1037864A1 (en)	2002-02-22
JP5335726B2 (ja)	2013-11-06
AU757293B2 (en)	2003-02-13
CA2336593A1 (en)	2000-01-13
JP2010174030A (ja)	2010-08-12
CA2684402A1 (en)	2000-01-13
EP1093363A1 (de)	2001-04-25
AUPP437698A0 (en)	1998-07-23
EP1754472A2 (de)	2007-02-21
ES2278449T3 (es)	2007-08-01
CA2336593C (en)	2010-06-29
DE69934010T2 (de)	2007-06-21
EP1754472B1 (de)	2014-07-23
NZ509504A (en)	2004-04-30
EP1093363B1 (de)	2006-11-15
WO2000001378A1 (en)	2000-01-13
US6475518B1 (en)	2002-11-05
DE69934010D1 (de)	2006-12-28

Legal Events

Date	Code	Title	Description
2007-05-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE345115T1 (de)	2006-12-15	Zusammensetzungen zur behandlung von chlamydiale assozierten krankheiten
DE60117043D1 (de)	2006-04-13	Behandlung von mukositis
ATE232862T1 (de)	2003-03-15	Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
ATE335499T1 (de)	2006-09-15	Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
ATE279942T1 (de)	2004-11-15	Mehrwertige impstoffzusammensetzung mit gemischten trägern
BR9913935A (pt)	2001-06-19	Métodos de tratamento e prevenção de infecção causada por pelo menos um vìrus da famìlia dos flaviviridae e doença associada com a dita infecção em um hospedeiro vivo
DE60235083D1 (de)	2010-03-04	Substituierte tetracyclin-verbindungen zur behandlung von malaria
EP0932613A4 (de)	2002-01-09	Expressionsblockierung von virulenten faktoren in s. aureus
DE60041753D1 (de)	2009-04-23	Arzneimittel zur behandlung von c. pneumoniae infektionen
DE69825128D1 (de)	2004-08-26	Verwendung von azithromycin zur topischen behandlung von augeninfektionen
BR0111989A (pt)	2003-04-01	Peptìdeos, composições e processos para o tratamento de burkholderia cepacia
DE69631381D1 (de)	2004-02-26	Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
PT775745E (pt)	2004-06-30	Aptameros inibidores de catepsina g
DK0824539T3 (da)	2001-09-24	Dialkyltiacumicin-forbindelser
DK1763339T3 (da)	2008-08-11	Orale antimikrobielle farmaceutiske præparater
ATE260097T1 (de)	2004-03-15	Hopfensäuren zur hemmung von staphylococcus aureus
DE60011601D1 (de)	2004-07-22	Rekombinantes sp-a zur behandlung und vorbeugung von pulmonaren infektionen und entzündungen
EP1496742A4 (de)	2007-04-11	Verwendung von nichtantibakteriellen tetrazyklin-analoga und ihren formulierungen für die behandlung von bakteriellen exotoxinen
DE69935662D1 (de)	2007-05-10	Mittel zur prävention/behandlung entzündlicher darmerkrankungen
BG101145A (bg)	1997-08-29	Използване на /s/-аденозил-l-метионин /саме/ i неговите физиологично съвместими соли за лечение нареперфузионно увреждане, причинено от временна фокална исхемиа
ATE196424T1 (de)	2000-10-15	Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten
ATE212229T1 (de)	2002-02-15	Bismut und antimikrobielle mittel enthaltende zusammensetzung zur verhütung und behandlung gastrointestinaler beschwerden
WO1998014567A3 (en)	1998-07-16	Methods and compositions for inhibiting bacterial growth
ATE298235T1 (de)	2005-07-15	Heilmittel und prophylaxe von störungen der intestinalen schleimhäute
DE69923117D1 (de)	2005-02-17	Verwendung von Homocysteinderivaten zur Behandlung von bakteriellen Infektionen